The properties and longitudinal experience of Chinese type A botulinum toxin for the treatment of focal dystonia and hemifacial spasm

Chinese Medical Sciences Journal

Volumn 18, Issue 4, 2003, Pages 254-259

  Wan, Xinhua ^a   Tang, Xiaofu ^a   Wang, Yinchun ^b  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b LANZHOU INSTITUTE OF BIOLOGICAL PRODUCTS   (China)

Author keywords

Botulinum toxin type A; Focal dystonia; Hemifacial spasm

Indexed keywords

ANTIALLERGIC AGENT; BOTULINUM TOXIN A; CBTXA;

ADOLESCENT; ADULT; AGED; ANIMAL EXPERIMENT; ARTICLE; BLEPHAROSPASM; CHINA; CHINESE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG ACTIVITY; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG PURITY; DRUG QUALITY; DRUG SAFETY; DYSPHAGIA; DYSTONIA; ECONOMIC ASPECT; FEMALE; FOLLOW UP; HEMIFACIAL SPASM; HUMAN; INJECTION; LONG TERM CARE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PAIN; PTOSIS; QUALITY OF LIFE; RASH; SCHOOL CHILD; SIDE EFFECT; SKIN BRUISING; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; WEIGHT REDUCTION;

EID: 0347764485     PISSN: 10019294     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. American Academy of Neurology Assessment: The clinical usefulness of botulinum toxin-A in treating neurologic disorders. Neurology 1990; 40: 1332-6.
2. Denislic M, Pirtosek Z, Vodusek DB, et al. Botulinum toxin in the treatment of neurological disorders. Ann New York Acad Sci 1994; 710: 76-87.
3. Hermanowicz N, Truong DD. Development of botulinum toxin therapy. West J Med 1995; 163:472-3.
4. Schantz EJ, Johnson EA. Botulinum toxin: the story of its development for the treatment of human disease. Persp Biol Med 1997; 40(4): 317-27.
5. Wang YC, Tang XF. Botulinum toxin and the clinical use. Chine J Neuroimmunol Neurol 1996; 3:124-7.
6. Tang XF, Wan XH, Huang G, et al. The treatment of focal muscle spasm with Botox and CBTXA-A. Chin J Neurol 1999; 32(3): 135-8.
7. Wan XF, Tang XF. Comparison of Botox and a Chinese type A botulinum toxin in cervical dystonia. Natl Med J China 1998; 78: 131-4.
8. Wan XH, Tang XF, Cui LY. Remote effects of local injection of botulinum toxin type A: single-fiber EMG studies. Acta Acad Med Sin 1999; 21(5): 362-7.
9. Kessler KR, Skutta M, Benecke R. Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency. J Neurol 1999; 246(4):265-74.
10. Dressler D. Clinical features of antibody-induced complete secondary failure of botulinum toxin therapy. Eur Neurol 2002; 48(1): 26-9.
11. Schnider P, Birner P, Moraru E, et al. Long-term treatment with botulinum toxin: dosage, treatment schedules and costs. Wien Klin Wochenschr 1999; 111(2): 59-65.
12. Naumann M, Toyka KV, Mansouri T B. Depletion of neutralizing antibodies resensitises a secondary non-responder to botulinum A neurotoxin. J Neurol Neurosurg Psychiatry 1998; 65 (6): 924-7.
13. Schantz EJ. Historical perspective. In: Jankovic J, Hallett M, editors. Therapy with botulinum toxin. New York: Marcel Dekker, 1994, XXV.